Literature DB >> 7160052

Effect of combination chemotherapy, duration of methotrexate administration, and patient's age on methotrexate pharmacokinetics.

F Lokiec, O Poirier, C Gisselbrecht, M Marty, M Boiron, Y Najean.   

Abstract

The kinetics of methotrexate were studied in a group of 59 patients after infusion of high doses. From the triexponential analysis of the serum concentration curve, rate constants and relative concentrations in non-circulating pools were calculated, using a linear 'mammillary' three-compartment model. No significant variation as a function of dose (300-6,000 mg/m2) was observed. In circumstances the rapidly exchanging pool was a reflection of the circulating pool, suggesting that it is an extravascular, protein-bound pool of methotrexate. Considerable variations of the relative concentration and rate constants of the slowly exchanging pool were observed to be a function of the duration of methotrexate infusion, the presence of other drugs, and the patient's age. If this compartment is assumed to include the target cells for methotrexate, then the large variations observed could be responsible for individual differences in toxicity and/or effectiveness.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7160052     DOI: 10.1007/bf00257746

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  16 in total

1.  Kinetic model for the disposition and metabolism of moderate and high-dose methotrexate (NSC-740) in man.

Authors:  P R Leme; P J Creaven; L M Allen; M Berman
Journal:  Cancer Chemother Rep       Date:  1975 Jul-Aug

2.  Pharmacokinetic monitoring of high-dose methotrexate. Early recognition of high-risk patients.

Authors:  W E Evans; C B Pratt; R H Taylor; L F Barker; W R Crom
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

3.  Pharmacokinetics of methotrexate.

Authors:  D H Huffman; S H Wan; D L Azarnoff; B Hogstraten
Journal:  Clin Pharmacol Ther       Date:  1973 Jul-Aug       Impact factor: 6.875

4.  Methotrexate pharmacokinetics.

Authors:  K B Bischoff; R L Dedrick; D S Zaharko; J A Longstreth
Journal:  J Pharm Sci       Date:  1971-08       Impact factor: 3.534

5.  Methotrexate infusions and intensive supportive care in the management of children with acute lymphocytic leukemia: follow-up report.

Authors:  I Djerassi
Journal:  Cancer Res       Date:  1967-12       Impact factor: 12.701

6.  Pharmacokinetics of high-dose methotrexate with citrovorum factor rescue.

Authors:  W H Isacoff; P F Morrison; J Aroesty; K L Willis; J B Block; T L Lincoln
Journal:  Cancer Treat Rep       Date:  1977-12

7.  Evaluation of enzyme immunoassay, radioassay, and radioimmunoassay of serum methotrexate, as compared with liquid chromatography.

Authors:  R G Buice; W E Evans; J Karas; C A Nicholas; P Sidhu; A B Straughn; M C Meyer; W R Crom
Journal:  Clin Chem       Date:  1980-12       Impact factor: 8.327

8.  Evaluation of 24-hour infusion of high-dose methotrexate--pharmacokinetics and toxicity.

Authors:  T S Goh; K Y Wong; B Lampkin; J O'Leary; D Gnarra
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

9.  Pharmacokinetic and clinical studies of 24-h infusions of high-dose methotrexate.

Authors:  H J Cohen; N Jaffe
Journal:  Cancer Chemother Pharmacol       Date:  1978       Impact factor: 3.333

10.  Weekly high-dose methotrexate-citrovorum factor in osteogenic sarcoma: pre-surgical treatment of primary tumor and of overt pulmonary metastases.

Authors:  N Jaffe; E Frei; D Traggis; H Watts
Journal:  Cancer       Date:  1977-01       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.